New hope for Tough-to-Treat colon cancer: old drug may help overcome resistance
NCT ID NCT05576896
Summary
This study is testing whether adding hydroxychloroquine (an existing drug) to a standard two-drug combination can help control advanced colon cancer that has a specific genetic change (BRAF V600E) and has progressed after at least one prior treatment. The researchers believe cancer cells use a survival process called autophagy to resist the standard drugs, and that hydroxychloroquine can block this process. The trial will enroll 43 patients to see if this three-drug combination is more effective at shrinking tumors and controlling the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.